The company, focused on developing therapies for retinal diseases, posted a loss of $0.38 per share for Q1 2025, wider than the $0.29 loss analysts had forecast. Revenue came in at $10.7 million, ...

Shares of Teva Pharmaceutical Industries Ltd ADR (NYSE: TEVA) surged 6.2% while Alvotech SA (NASDAQ: ALVO) climbed 3.5% in ...